Trials / Completed
CompletedNCT00502060
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
A Phase I Open-Label Study to Assess the Safety, Tolerability and PK of Ascending Multiple Oral Doses of AZD2171 When co-Administered With Fixed Multiple Oral Doses of ZD1839 (250mg or 500mg Once Daily) in Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2171 | |
| DRUG | ZD1839 |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2006-06-01
- Completion
- 2006-06-01
- First posted
- 2007-07-17
- Last updated
- 2009-05-14
Locations
3 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00502060. Inclusion in this directory is not an endorsement.